Benjamin F. Edwards & Company’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Benjamin F. Edwards & Company’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,902	Closed	-$338K	–	1767
2023 Q2	$338K	Sell	12,902 -264	-2%	-$6.97K	0.01%	597
2023 Q1	$344K	Buy	13,166 +12	+0.1%	+$322	0.01%	576
2022 Q4	$361K	Hold	13,154	–	–	0.02%	550
2022 Q3	$316K	Buy	+13,154	New	+$340K	0.02%	538

Other funds holding FTXH

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

OWA

Outlook Wealth Advisors Shenandoah, Texas $413M AUM 19.55% 1-Year Est. Return

Benjamin F. Edwards & Company's FTXH Position: Q3 2023 in Review

Benjamin F. Edwards & Company sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2023, closing a stake of 12,902 shares — an estimated $338K sold.

Benjamin F. Edwards & Company first reported a position in FTXH in Q3 2022 and held it in 4 quarters. The position peaked at $361K in Q4 2022. 19 funds tracked by Wall St. Rank hold FTXH as of Q3 2023.

Benjamin F. Edwards & Company reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q3 2023 after selling out during the quarter.
Benjamin F. Edwards & Company sold 12,902 First Trust Nasdaq Pharmaceuticals ETF shares in Q3 2023, an estimated $338K.
Benjamin F. Edwards & Company first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2022 and held it in 4 quarters.
Benjamin F. Edwards & Company's First Trust Nasdaq Pharmaceuticals ETF position peaked at $361K in Q4 2022.
19 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2023, filed 13 Nov 2023.